Luna Emery is a financial writer. She graduated with a degree in Economics. She has contributed to major financial websites and print publications for over 8 years. She handles much of this site's news coverage for …
Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of the iShares Nasdaq Biotechnology ETF (IBB). It rose 6.6% and outperformed the SPDR S&P 500 ETF (SPY), which rose 0.5% for …
Melanoma
Celldex Therapeutics (CLDX) : 9 analysts are covering Celldex Therapeutics (CLDX) and their average rating on the stock is 1.89, which is read as a Buy. 5 equity analysts believe that the stock has a bright future and the …
Alpha One uses algorithm based analytics for reaching stock sentiment. For the purpose, it takes in reference the published content on various online channels on a given company. Celldex Therapeutics, Inc. …
CLDX’s 50-day average is $3.78 and its two hundred day average is $4.09. The last stock close price is up …
Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate …
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says. Celldex Therapeutics (CLDX) reported a …
Celldex Therapeutics, Inc. (CLDX) up 10.08 per cent in the past week, is under coverage of 11 analysts who collectively recommend a hold rating on stock. 6 of the analysts have a buy or better rating; the 0 sells versus …
The firm set “Buy” rating on CLDX stock. About 921,302 shares traded hands. Celldex Therapeutics, Inc. (CLDX) has declined 29.45% since April 5, 2016 and is downtrending. It has underperformed by 31.41% the S&P500. …
Celldex Therapeutics Inc. fell after the Federal Reserve issued cautionary comments about stock values, “particularly those for smaller firms in the social media and biotechnology industries.” The Nasdaq …